deferasirox has been researched along with Acute Lymphoid Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abedi, M; Esmaeili, A; Rahgozar, S | 1 |
| Bahcebasi, S; Cetin, M; Deniz, K; Eser, B; Kaynar, L; Kurnaz, F; Ozturk, A; Pala, C; Sivgin, S; Unal, A; Uzer, E | 1 |
2 other study(ies) available for deferasirox and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Iron protects childhood acute lymphoblastic leukemia cells from methotrexate cytotoxicity.
Topics: Acetylcysteine; Bone Marrow; Cell Line, Tumor; Cell Survival; Child; Child, Preschool; Deferasirox; Drug Resistance, Neoplasm; Female; Ferric Compounds; Free Radical Scavengers; Humans; Infant; Inhibitory Concentration 50; Iron; Iron Chelating Agents; Male; Methotrexate; Multidrug Resistance-Associated Proteins; NF-E2-Related Factor 2; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2; Quaternary Ammonium Compounds; Reactive Oxygen Species; RNA, Messenger; Superoxide Dismutase; Transcriptome; Up-Regulation | 2020 |
Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).
Topics: Adolescent; Adult; Benzoates; Deferasirox; Female; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Kidney; Leukemia; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Phlebotomy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Triazoles; Young Adult | 2012 |